Cumberland Pharmaceuticals closes transaction with Apotex

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has completed a strategic transaction with Apotex, a Canadian-based pharmaceutical company, to integrate Cumberland’s U.S. branded pharmaceutical business into Apotex’s portfolio. Under the terms of the agreement, Apotex acquired Cumberland’s line of branded pharmaceuticals for a cash consideration of $100 million. The transaction, which was subject to shareholder approval, allows Cumberland to focus on its pipeline of orphan drug candidates aimed at addressing unmet medical needs.

Cumberland will retain ownership of its development-stage product candidates, including ifetroban, which is being evaluated in clinical trials for conditions such as cardiomyopathy associated with Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. The company also maintains its majority stake in Cumberland Emerging Technologies Inc.

Apotex stated that the acquisition expands its U.S. specialty and hospital-focused business with a diversified portfolio of products across acute care, oncology, infectious disease, and gastroenterology. The transaction is expected to enhance Apotex’s commercial capabilities and strengthen its position in the institutional channel.

The integration of Cumberland’s commercial operations is intended to improve patient access to specialty treatments and support Apotex’s mission of delivering high-quality medicines. Both companies emphasized the transaction’s potential to create value for shareholders and enhance patient care outcomes.